DoP Announces Exemption For Startups And MSEs To Participate In Tender For Long & Short Term Studies

New Delhi : The Department of Pharmaceuticals (DoP) has amended its Request for Proposal format released to invite the tended register for selection of reputed empanelled agencies for conducting long term and short term studies related to pharmaceutical and medical devices sector to allow startups and Micro and Small Enterprises to take part in the tender process with some exemptions.

The Department, in its RFP for both long term and short term studies, added one more paragraphs under the MSME classification, stating that in line with the Ministry of Micro, Small and Medium Enterprises’ policy circular in March, 2016, on relaxation of norms for start ups and MSEs in public procurement on prior experience and prior turnover criteria, these criteria are exempted for the start ups and MSEs for this tender, subject to meeting of quality and technical specifications.

The Startup enterprises shall submit Start Up India recognition certificates issued by the Department of Industrial Policy and Promotion (DIPP) of Ministry of Commerce and Industry in order to be considered for relaxation in prior experience and prior turnover, it said.

The MSEs with valid DIPP certificate and registered with the agencies or bodies including the district industries centres, Khadki and Village Industries Commission, Khadi and Village Industries Board, National Small Industries Corporation, Directorate of Handicrafts and Handloom, MSEs having Udyog Aadhar memorandum, or any other body specified by Ministry of MSMEs, are exempted from payment of bid fees and earnest money deposit.

The MSEs who have applied for registration or renewal of registration with any of these agencies but have not obtained the valid certificate as on close date of the tender are not eligible for exemption or preference. All other terms and conditions remain unchanged, said the corrigendum issued by the DoP.

The Department has invited sealed bids from reputed experienced empanelled agencies with Government of India to conduct long term and short term studies related to pharmaceutical and medical devices sector, through tender notice on October 22, 2021.

These expert bodies are expected to help the government frame policies, monitoring and corrective measures in the pharmaceuticals and medical devices sector.

The first two topics in the short-term studies for which it has floated RFP include tracking of medicines across the supply chain and assessing skill requirements of the Indian pharma industry, both for a duration of three months.

For the long-term studies, it has proposed eight topics, including a four month study on the impact of DPCO 2013 on the prices of cardiac stents, knee implants and six medical devices – oxygen concentrators, pulse oximeter, glucometer, BP monitor, nebuliser and digital thermometer on the industry and consumers in terms of availability and affordability, to assess the impact of price control on medical devices and equipment on the industry and consumers in terms of availability and affordability.

The other long term studies include an assessment of procurement of medical devices in the public sector; surveys on medical devices and pharma clusters to evaluate their contribution to overall production and suggest improvements; study on the uniform code of pharmaceutical marketing practices, among others.

  • Related Posts

    • Pharma
    • December 23, 2024
    • 63 views
    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

    • Pharma
    • December 23, 2024
    • 90 views
    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt